Re‐challenging chemotherapy after pembrolizumab in platinum‐refractory urothelial carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Re‐challenging chemotherapy after pembrolizumab in platinum‐refractory urothelial carcinoma

Published:2022-09-26 Issue:4 Volume:131 Page:477-485
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU International

Author:

Uchimoto Taizo¹,Fukushima Tatsuo¹,Komura Kazumasa¹^ORCID,Fukuokaya Wataru²^ORCID,Adachi Takahiro³,Hashimoto Takeshi³,Yoshizawa Atsuhiko⁴,Nakamura Ko¹,Yano Yusuke¹,Nishimura Kazuki¹,Nishio Kyosuke¹,Nakamori Keita¹,Iwatani Kosuke²,Yamamoto Shutaro²,Urabe Fumihiko²,Mori Keiichiro²^ORCID,Yanagisawa Takafumi²^ORCID,Tsuduki Shunsuke²,Takahara Kiyoshi⁴^ORCID,Inamoto Teruo¹,Miki Jun²^ORCID,Kimura Takahiro²,Ohno Yoshio³,Shiroki Ryoichi⁴,Egawa Shin²,Azuma Haruhito¹

Affiliation:

1. Department of Urology Osaka Medical and Pharmaceutical University Takatsuki City, Osaka Japan

2. Department of Urology The Jikei University School of Medicine Minato‐ku, Tokyo Japan

3. Department of Urology Tokyo Medical University Shinjuku‐ku, Tokyo Japan

4. Department of Urology Fujita‐Health University School of Medicine Toyoake City, Aichi Japan

Funder

Japan Society for the Promotion of Science

Osaka Medical Research Foundation for Intractable Diseases

Takeda Science Foundation

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bju.15893

Reference23 articles.

1. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

2. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

3. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

4. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

5. Paclitaxel and carboplatin chemotherapy after platinum‑based chemotherapy and pembrolizumab for metastatic urothelial carcinoma

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors;Targeted Oncology;2024-03-28

2. Is there a role for pembrolizumab beyond progression in urothelial carcinoma?;BJU International;2023-12-18

3. Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review;Japanese Journal of Clinical Oncology;2023-12-18

4. Predicting Objective Response of Pembrolizumab in Platinum-Refractory Urothelial Carcinoma Based on Neutrophil-Lymphocyte Ratio Fluctuation and Liver Metastases;Oncology;2023-10-13

5. Enfortumab vedotin prolonged overall survival in metastatic urothelial carcinoma compared to standard of care following pembrolizumab treatment;2023-10-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3